-
Pembrolizumab (MK-3475, lambrolizumab), a highly selective humanized monoclonal immunoglobulin G4 (IgG4)/kappa isotype antibody that blocks the interaction between PD-1 and its ligands, has demonstrated antitumor activity in multiple tumor types.
More
-
Nivolumab (BMS-936558, MDX-1106, ONO-4538), an anti-PD-1 monoclonal antibody, has been reported to have anti- tumor effects and approved for the treatment of unresectable or metastatic melanoma in treatment-refractory patients.
More
-
Obinutuzumab (Gazyva) is a unique, third-generation, fully humanized glycoengineered IgG1 type II anti-CD20 monoclonal antibody monoclonal antibody, approved in chronic lymphocytic leukemia (B-CLL) and follicular lymphoma (FL).
More
-
Ofatumumab, a humanized anti-CD20 monoclonal antibody, has been proven to be effective in the treatment of relapsed, refractory CLL.
More
-
Omalizumab (rhuMAb-E25), an anti-IgE antibody, inhibits the interaction between IgE and FcϵRI, is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe persistent allergic asthma (AA).
More
